Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Endoplasmic reticulum (ER) alpha-glucosidase II is a key enzyme involved in the processing of N-linked glycans on nascent glycoproteins within the ER. It acts sequentially after alpha-glucosidase I, trimming glucose residues from N-linked oligosaccharides, which is essential for proper protein folding and quality control in eukaryotic cells. It is a heterodimeric enzyme composed of an alpha (catalytic) and a beta (localization) subunit. Inhibitors targeting this enzyme can disrupt viral morphogenesis and have shown efficacy against various viruses by impairing viral protein maturation.
Inhibition of alpha-glucosidase II, leading to disruption of N-glycan processing and glycoprotein folding
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Endoplasmic reticulum alpha-glucosidase II (Glucosidase II).